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Mouse intestinal microbiota reduction 
favors local intestinal immunity triggered 
by antigens displayed in Bacillus subtilis biofilm
Cédric M. Vogt1, Monika Hilbe2, Mathias Ackermann1, Claudio Aguilar3 and Catherine Eichwald1* 
Abstract 
Background: We previously engineered Bacillus subtilis to express an antigen of interest fused to TasA in a biofilm. B. 
subtilis has several properties such as sporulation, biofilm formation and probiotic ability that were used for the oral 
application of recombinant spores harboring Echinococcus granulosus paramyosin and tropomyosin immunogenic 
peptides that resulted in the elicitation of a specific humoral immune response in a dog model.
Results: In order to advance our understanding of the research in oral immunization practices using recombinant 
B. subtilis spores, we describe here an affordable animal model. In this study, we show clear evidence indicating that 
a niche is required for B. subtilis recombinant spores to colonize the densely populated mice intestinal microbiota. 
The reduction of intestinal microbiota with an antibiotic treatment resulted in a positive elicitation of local humoral 
immune response in BALB/c mice after oral application of recombinant B. subtilis spores harboring TasA fused to E. 
granulosus (102-207) EgTrp immunogenic peptide. Our results were supported by a lasting prevalence of spores in 
mice feces up to 50 days after immunization and by the presence of specific secretory IgA, isolated from feces, against 
E. granulosus tropomyosin.
Conclusions: The reduction of mouse intestinal microbiota allowed the elicitation of a local humoral immune 
response in mice after oral application with spores of B. subtilis harboring immunogenic peptides against E. 
granulosus.
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Background
Bacillus subtilis is a Gram-positive bacterium that has 
several attractive properties with high potential in bio-
applications such as vaccines [1–3] or bioremediation 
[4, 5]. One of these properties is the capacity to form 
endospores upon nutrient starvation [6, 7]. The B. subti-
lis spores have been vastly adopted as a carrier in immu-
nization strategies because of their resistance to harsh 
conditions as low pH, high temperature, and noxious 
chemicals. In this context, methods as decoration of the 
spores by direct fusion with different coat proteins [8, 9] 
or adsorption [10–12] with the antigen of interest illus-
trate the versatility of the spores as an antigen carrier. 
Another property of B. subtilis is the ability to form archi-
tecturally complex communities termed biofilms, which 
self-produce an extracellular matrix comprised of lipids, 
proteins exhibiting amyloid-like properties, extracellular 
DNA and exopolysaccharides [13]. Interestingly, evidence 
suggests that B. subtilis can develop biofilms in the gut 
of living organisms [14, 15]. This is true for some non-
domesticated laboratory B. subtilis strains as NCIB 3610 
[16, 17]. We recently showed that it is possible to express 
heterologous proteins in a B. subtilis biofilm by fusion to 
the C-terminus of the biofilm matrix protein, TasA [18]. 
Optimized expression of the heterologous protein was 
established using a tasA/sinR genetic background, where 
SinR is a repressor of the tapA-sipW-tasA operon, among 
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other genes [17, 19]. A third feature corresponds to its 
probiotic properties in human and livestock [20–22]. By 
combining these properties, we recently showed that it is 
possible, in a dog model, to elicit a local humoral immune 
response against enteric antigens such as E. granulosus 
parasite [23]. In this dog model, the recombinant spores 
were able to bypass the stomach barrier and then form, 
after germination, a biofilm in the intestine that displayed 
an antigen within its matrix, allowing the stimulation of 
gut-associated lymphoid tissue (GALT) and thereby, elic-
iting a local humoral immune response.
In the present study, we tested the local humoral 
immune response in the intestine of BALB/c mice, orally 
applied with recombinant spores of B. subtilis harboring 
a TasA fusion to the E. granulosus immunogenic peptide 
(102-207) EgTrp. We show that the elicited intestinal 
humoral immune response is favored when providing a 
niche to recombinant spores in the intestinal microbiota.
Results
Oral application of recombinant B. subtilis spores in mice
We first showed that B. subtilis was found in the mice 
intestine expressing TasA, even after the oral inocu-
lation with recombinant B. subtilis tasA/lux/TasA-
mCherry ([23] and Table  1) and that recombinant 
vegetative cells were not found in mice feces after 6 days 
post-inoculation (Additional file  1: Figure  S1a and b). 
Our data also show that 64–93.5% of the orally applied 
recombinant B. subtilis spores are retained in the mice 
gut (Additional file  1: Figure  S1c and d). Additionally, 
no pathologic changes, like inflammatory, degenera-
tive or neoplastic changes were observed in the small 
or in the large intestine sections of all mice treated with 
recombinant B. subtilis spores when compared with 
untreated animals (Additional file  1: Figure  S1e). Col-
lectively, our data suggest that spores germinate in the 
gut of mice. To investigate if recombinant spores of B. 
subtilis tasA/sinR (102-207) EgTrp, hereafter named B. 
subtilis (102-207)EgTrp, (Fig. 1a and Table 1) can elicit 
a local intestinal humoral immune response in mice, we 
provided the recombinant spores via oral gavage. For 
this purpose and as depicted in Fig.  1b, three groups 
of mice were treated at days 1, 21 and 42 with saline 
solution (placebo), or with 5 × 1010 CFU of recombi-
nant spores of B. subtilis tasA/sinR (group tasA/sinR) 
or 5 × 1010 CFU of recombinant spores of B. subtilis 
(102-207)EgTrp (group (102-207)EgTrp). Mice were 
isolated into individual cages to determine the number 
of shed spores after oral application and feces were col-
lected every 24 h until day 6 and also on days 20, 41 and 
50 of the scheduled treatment. As observed in Fig. 1c, 
mice applied with recombinant spores of B. subtilis 
tasA/sinR or (102-207)EgTrp exhibited a decline in the 
shedding of recombinant spores after 4 days post-appli-
cation. Additionally, we estimated that the total num-
ber of recombinant spores of B. subtilis tasA/sinR or 
(102-207) EgTrp strains retained in the gut correspond 
to 91% and 99%, respectively. We could not detect 
recombinant spores in the feces of animals before the 
subsequent oral applications (days 21 and 42) or at 
experiment termination (day 50) (Fig.  1d). Next, we 
tested if mice could elicit a humoral intestinal immune 
response against E. granulosus antigen EgTrp by test-
ing immunoglobulins extracted from feces at day 50 
through indirect ELISA coated with B. subtilis biofilm 
extracts expressing (102-207)EgTrp antigen, biofilm 
extract of B. subtilis tasA/sinR, recombinant  H6-EgTrp 
peptide or an irrelevant antigen such is  H6-mCherry. 
None of the experimental animal groups showed a pos-
itive elicitation of the local humoral immune response 
against the tested antigens (Fig. 1e). Similar results were 
obtained when tested the mice sera of day 50, which 
unveil no elicitation of the humoral immune response 
of neither IgG (Additional file  2: Figure  S2a) nor IgA 
(Fig. 1f ). Also, the animals remained healthy during the 
whole procedure as denoted by the lack of difference in 
the mean body weight among the experimental groups 
(Additional file 2: Figure S2c) and the absence of symp-
toms such as diarrhea, hypothermia, and mastocytosis. 
Thus, the recombinant spores of B. subtilis seem not 
able to elicit an immune response under the conditions 
tested in these experiments.
Table 1 Bacillus subtilis strains used in this study
a   Kmr: kanamycin resistance;  Spcr: spectinomycin resistance;  Cmr: chloramphenicol resistance;  MLSr: macrolide-lincosamide-streptogramin B (erythromycin and 
lincomycin) resistance
Strain Genotypea Reference/ source
tasA/SinR tasA-sinR::Kmr Vogt et al. [18]
tasA/sinR/TasA-(102-207)EgTrp tasA-sinR::Kmr; amyE::yqxM-sipM-tasA-(102-207)EgTrp  Spcr Vogt et al. [18]
wt/lux lacA::PtasA-luxCDABE  Erm
r Vogt et al. [23]
tasA/lux/TasA-mCherry tasA::Kmr; lacA::PtasA-luxCDABE  MLS
r; AmyE::yqxM-sipW-tasA-mCherry  Cmr Vogt et al. [23]
tasA/sinR/lux/TasA-mCherry tasA::KmrSinR::Spcr; lacA::PtasA-luxCDABE  MLS
r; AmyE::yqxM-sipW-tasA-mCherry  Cmr Vogt et al. [23]
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Reduction of the intestinal microbiota favors local immune 
response after oral application of recombinant B. subtilis 
spores in mice
To stimulate the GALT with a consequent elicitation of 
a humoral immune response against the presented anti-
gens, the spores of B. subtilis require a niche where to 
germinate, colonize and form a biofilm. However, the 
efficiency of this process may be severely hampered by 
the densely populated host intestinal microbiota, which 
could be actively competing for the same niche. We 
hypothesized that this competition could be of differ-
ent nature such as for nutrient availability [24] or space 
competition, impeding the colonization of new bacterial 
species [25]. In any of these circumstances, the reduction 
of the intestinal microbiota before the oral application of 
recombinant spores of B. subtilis could provide a chance 
for successful colonization and subsequent biofilm for-
mation, which in turn may elicit a local humoral immune 
Fig. 1 Lack of immune response after oral application with recombinant B. subtilis spores in mice. a Schematic representation of tapA operon 
carrying E. granulosus immunogenic peptide EgTrp fused in frame at the 3’end of tasA. tapA, anchoring and assembly protein; sipW, signal peptidase 
and tasA, main protein matrix. The amino acid region corresponding to the immunogenic peptide is indicated. For simplicity of the figures, 
TasA-(102-207)EgTrp is named as (102-207)EgTrp. Diagram not to scale. b Schematic schedule for the oral application of recombinant B. subtilis 
spores in mice. Three groups of six animals each were orally provided with (i) saline solution (placebo), spores of B. subtilis tasA/sinR and (iii) spores 
of B. subtilis (102-207)EgTrp. The animals were orally applied with 5 × 1010 CFU per dose on days 1, 21, 42. Feces were collected daily from days 1–6 
and on days 20, 41 and 50. Quantification of a daily number of spores in feces of mice of the indicated groups after day 1 (c) and on days 20, 41 and 
50 (d) post-oral application. All data are represented as mean ± SEM. The local intestinal humoral immune response, fecal sIgA (e) and serological 
IgA (f) were obtained by indirect ELISA coated with biofilm extract of B. subtilis (102-207)EgTrp, biofilm extract of B. subtilis tasA/sinR, recombinant 
 H6-EgTrp or recombinant  H6-mCherry. The tested animal groups are indicated
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response. To test this hypothesis, we treated mice for five 
consecutive days with an antibiotic cocktail [26]. The 
effective reduction of the intestinal microbiota was cor-
roborated by the absence of bacterial colonies isolated 
from feces in three different culture media such as Luria-
Bertani, brain heart infusion and nutrient broth (Addi-
tional file 3: Figure S3 a, b and c). Of note, the antibiotic 
treatment had no detrimental effect on the mice health 
as denoted by similar bodyweight among untreated and 
treated animals (Additional file  3: Figure  S3d). Thus, as 
described in Fig. 2a, all groups of mice were first treated 
for 5  days with an antibiotic cocktail, followed by three 
oral applications of 5 × 1010 CFU of recombinant spores 
per dose on days 1, 21 and 42. All animals were sacrificed 
on day 50. The animals were divided, as above, into three 
experimental groups: (i) placebo, (ii) tasA/sinR and (iii) 
(102-207)EgTrp. As in the previous experiment, mice 
shed recombinant spores until the fourth day from the 
Fig. 2 Reduction of intestinal microbiota elicits a local humoral immune response. a Schematic schedule for the oral application of recombinant B. 
subtilis spores in mice. All the animals were treated with an antibiotic (ABX) cocktail for 5 days before the first application of recombinant B. subtilis 
spores. Three groups of six BALB/c mice each were orally provided with (i) saline solution (placebo), (ii) spores of B. subtilis tasA/sinR and (iii) spores of 
B. subtilis (102-207)EgTrp. The animals were orally applied with 5 × 1010 CFU per dose on days 1, 21, 42. Feces were collected daily from days 1–6 and 
on days 20, 41 and 50. Blood samples were collected on days 1, 21, 42 and 50. Quantification of the daily total number of spores (CFU) in feces of 
mice of the indicated groups after (b) day 1 and on (c) days 20, 41 and 50 post-oral application. The data represent the mean ± SEM. Determination 
of the local intestinal humoral immune response, fecal sIgA (d) and serological IgA (e) using indirect ELISA coated with biofilm extract of B. subtilis 
(102-207)EgTrp, biofilm extract of B. subtilis tasA/sinR, recombinant  H6-EgTrp or recombinant  H6-mCherry. The tested animal groups are indicated. 
The data represent the mean ± SEM, and t-test unpaired two-tailed; * p < 0.05; ** p < 0.01
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first oral application (Fig.  2b). The number of recombi-
nant spores retained in the gut was 99.9% for B. subtilis 
tasA/sinR and 97.6% for (102-207)EgTrp. Surprisingly, 
recombinant spores from both tasA/sinR and (102-207)
EgTrp groups were readily detected at day 50 in the mice 
feces (Fig. 2c). The local intestinal humoral immunity was 
determined using an indirect ELISA coated with either an 
EgTrp biofilm extract, tasA/sinR biofilm extract, recom-
binant  H6-EgTrp or recombinant  H6-mCherry. Interest-
ingly, the secretory IgA (sIgA) isolated from feces of mice 
of the (102-207)EgTrp group recognized specifically the 
biofilm extracts harboring the heterologous expression 
of the immunogenic peptide EgTrp (Fig. 2d). In the same 
conditions, no recognition by sIgA isolated from mice 
feces of the placebo and tasA/sinR groups was observed 
for EgTrp expressed in biofilm extracts. Importantly, the 
lack of TasA and SinR in biofilm extracts (i.e., tasA/sinR 
biofilm extracts), resulted in no local humoral response 
for the three tested groups. Additionally, no response for 
sIgA was obtained for  H6-EgTrp or  H6-mCherry. Mice 
did not induce any serological humoral immune response 
for the tested antigens in an IgG (Additional file  1: Fig-
ure  S1b) or IgA context (Fig.  2e). Between the experi-
mental groups, no differences were observed in animal 
body weight (Additional file 2: Figure S2d), as well as no 
signs of diarrhea, hypothermia or mastocytosis after pre-
treatment with antibiotics, followed by oral application of 
recombinant B. subtilis spores.
Discussion
It is of high interest to perform antigen tests aimed at 
vaccine development in affordable animal models such 
as rodents, being mice (as BALB/c strain) frequently the 
model of choice. Initial evidence suggested that recom-
binant B. subtilis spores germinate in the gut of BALB/ 
c mice without generating adverse effects. There-
fore in an attempt to evaluate the effectiveness of our 
method, based on the display of antigens in biofilms, we 
used a previously tested recombinant B. subtilis (102-
207)EgTrp that elicited a positive humoral immune 
response in dogs [23]. The antigen (102-207) EgTrp 
corresponds to tropomyosin, an immunogenic peptide 
of Echinococcus granulosus, described previously by 
Pétavy and collaborators [27, 28]. E. granulosus cestode 
is the causative agent for cystic echinococcosis, respon-
sible for high human morbidity and mortality and hav-
ing a high economic impact on livestock [29–31]. In 
our first trial in mice, we could not detect an elicita-
tion of the local immune response after three oral doses 
of recombinant B. subtilis spores. This observation 
was not surprising, and it is consistent with previous 
observations [9, 32–39], where even nine consecutive 
oral doses with B. subtilis spores evoked weak or null 
immune response compared to similar conditions after 
intranasal immunization in mice [8]. The pre-treatment 
with antibiotics to reduce the density of gut microbi-
ota is a standard procedure in other mouse models of 
enteric infection [9, 40]. In our experimental setting, 
we administrated an antibiotic cocktail [26] for 5 days 
before the first oral application of recombinant B. sub-
tilis spores. The persistence of the recombinant spores 
in the gut was determined by their prevalence in feces 
at day 50 post-application compared with the mice 
untreated with antibiotics in the same conditions. The 
spore persistence suggests that recombinant B. subtilis 
spores were able to find a niche in the gut (coloniza-
tion), followed by germination, biofilm formation, and 
subsequent sporulation. Additionally, an elicitation of 
local humoral immune response as determined by the 
presence of specific sIgA recognizing EgTrp. There-
fore, the decrease of the intestinal microbiota of mice, 
colonized for at least 1000 different bacterial species 
(40), is a requisite for the settlement of recombinant 
B. subtilis spores. Previous evidence demonstrates that 
B. subtilis naturally colonize the gut of humans [14], 
dogs [23], and even grass carps [41], suggesting that 
B. subtilis cannot be considered as an allochthonous 
microorganism. Interestingly, the generated immuno-
globulins recognized the EgTrp antigen peptides only 
when present in a biofilm extract but not the one from 
the recombinant purified  H6-(102-278)EgTrp. In this 
context, we recently showed [23] that dogs treated 
orally with recombinant spores of B. subtilis (102-207)
Egtrp elicited a humoral immune response recognizing 
specifically recombinant purified  H6-EgTrp. Our results 
suggest that the biofilm TasA-(102-207)EgTrp fusion 
displayed in the gut mice got selected by immunoglob-
ulins through specific conformation that is not forged 
by  H6-EgTrp [42, 43]. This outcome also confirms the 
dissimilarities between the intestinal immune system of 
mice and that of dogs. It is important to highlight that 
the results obtained here cannot necessarily apply to a 
different animal model. The specificity of the humoral 
response was denoted by the lack of recognition of 
unrelated antigens as  H6-mCherry by sIgA. It is of note 
that we could not distinguish a serum-specific IgA in 
any of the experimental settings tested. As expected, 
the use of recombinant B. subtilis spores resulted safe 
in mice. Our recombinant spores under the conditions 
described do not alter the health status of treated mice 
when compared to its control pairs, as denoted by no 
discrepancy in their body weight, pathological states 
(like hypothermia, diarrhea or mastocytosis) and by 
infiltration of inflammatory cells in the small and large 
intestine.
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Conclusions
In this work, we provide evidence that a reduction in the 
intestinal microbiota in mice could settle the basis for 
favoring an oral immunization using recombinant B. sub-
tilis spores.
Methods
Ethics statement
All the mouse experiments were performed accord-
ing to the guidelines of the animal experimentation law 
(SR 455.163; TVV) of the Swiss federal government. 
The Cantonal Veterinary Office of Zurich, Switzerland, 
approved the protocols under animal experimentation 
number 104/2012.
Bacillus subtilis strains, media and culture conditions
The B. subtilis strains used in this study were previously 
described by Vogt et  al. [18]. For routine growth and 
spore quantification, cells were propagated on Luria-Ber-
tani (LB) medium. The final concentrations of antibiotics 
used for the B. subtilis strains were as follows: 100  μg/
ml for spectinomycin (Spc) and 10 μg/ml for kanamycin 
(Km).
Plasmid constructions
pQE32-(102-278)EgTrp and pQE32-mCherry were previ-
ously described by Vogt et al. [23].
Production of recombinant B. subtilis spores
The recombinant spores were produced and purified as 
described by Vogt et al. [18].
Experimental administration of recombinant B. subtilis 
spores in mice
Intragastric gavage was orally applied to groups of six 
mice (females, BALB/c, 6 weeks old) with 5 × 1010 CFU 
of recombinant spores of B. subtilis in a final volume of 
200  µl PBS per dose on days 1, 21 and 42. The placebo 
group was orally applied with 200 µl PBS. Mice were iso-
lated into single cages for collection of feces every 24 h, 
on days 1 to 6 and on days 20, 41 and 50. Blood sam-
ples were collected by tail-bleeding the day before the 
application of a spores dose and at day 50. The serum 
was used to test the humoral response against the anti-
gen of interest. All animals were sacrificed on day 50 
post-application.
Mouse intestinal microbiota reduction
When indicated, mice were treated with an antibiotic 
mixture for the elimination of the gut microbiota as 
described by Shan et al. [26]. For this purpose, a mixture 
containing 0.5  mg/ml ampicillin (PanReac AppliChem, 
Spain), 0.5  mg/ml gentamycin (PanReac AppliChem, 
Spain), 0.25  mg/ml vancomycin (Alfa Aesar, Germany), 
metronidazole (Alfa Aesar, Germany), and 20  mg/ml 
sucrose (Sigma) dissolved in sterile drinking water was 
provided as source of water to mice for 5 days. The reduc-
tion of the intestinal microbiota was monitored by count-
ing the number of bacterial colonies isolated from feces 
in non-selective media, such as LB, heart-brain infusion 
and nutrient broth semi-solid media.
Quantification of spores in feces
Feces of single-caged mice were collected throughout 
24  h. The feces were resuspended to a concentration 
of 0.2  g/ml in PBS, homogenized with vortex for 30  s. 
Then, a 300 µl aliquot of feces resuspension was heated 
for 20 min at 80 °C to kill vegetative cells. Serial dilutions 
were plated on selective semi-solid LB agar containing 
10  µg/ml kanamycin to determine viable recombinant 
spores. The spore number per gram of feces was obtained 
dividing the colony forming units (CFU) by the amount 
in grams of feces.
Indirect ELISA
The assays were performed as described in detail by Vogt 
et al. [23]. For the extraction of secretory antibodies (sIgA), 
fecal samples were collected throughout 24  h from mice 
isolated in single cages and stored at − 20 °C until analy-
sis. One gram of feces was resuspended in 5 ml PBS, vor-
tex homogenized for 30  s and centrifuged at 800×g for 
10 min. Then, 360 µl of recovered supernatant was mixed 
with 40  µl of feces buffer (1% BSA, 0.01% Triton X-100, 
0.1% 2-mercaptoethanol and protease inhibitor (cOm-
plete™ EDTA-free protease inhibitor cocktail, Roche, Swit-
zerland)) and kept in ice. Recombinant purified protein 
(500 ng/well) or 72 h biofilm extract  (OD600nm of 0.0002/
well) in 0.2  M bicarbonate buffer pH 9.4 was coated for 
16 h at 4 °C in a 96 well multi-well plates (Nunc-Immuno 
Maxisorp, Thermo Scientific). Plates were incubated for 
2 h at room temperature with blocking buffer (1% BSA in 
PBS). A 100 µl aliquot of feces mixture was incubated for 
2 h at 37 °C. This was followed by incubation of the plates 
for 1  h at 37  °C with goat anti-mouse IgA conjugated to 
peroxidase (diluted 1:600, Sigma) or rabbit anti-mouse IgG 
(whole molecule) conjugated to peroxidase (diluted 1:2000, 
Sigma) both diluted in 1% BSA-PBS. The plates were incu-
bated with 100 µl per well of 3,3’,5,5’-tetramethylbenzidine 
(TMB) substrate (ThermoFisher Scientific) in the dark for 
30 min at room temperature, and the reaction was stopped 
by the addition of 100 µl 1 M  H2SO4. The plates were read 
using an SLT 340 ATTC Tecan microplate reader (Tecan 
US Inc.) at an  OD450nm. The data were analyzed and pro-
cessed using  Microsoft®Excel® for MAC 2011. The cut-off 
was determined as the average of three negative controls. 
The negative control value was obtained by incubation of 
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the antigen followed by the secondary antibody conjugated 
to HRP. The cut-off was subtracted from all the sample val-
ues. Each value has been subtracted from its corresponding 
pre-immune (PI) value.
Expression and purification of  H6‑tagged proteins
H6-EgTrp and  H6-mCherry were expressed in Escherichia 
coli M15 (pREP4) (Qiagen) transformed with pQE32-
(102-278)EgTrp and pQE32-mCherry, as described in 
detail by Vogt et al. [23].
Preparation of biofilm extract
For the preparation of biofilms, cells were scraped from 
overnight growth on LB-agar plates, resuspended in LB 
liquid medium to an  OD600 nm of 1, and then 2 µl of this 
suspension was spotted on MSgg solid medium [16]. 
Biofilms were incubated at 30  °C. At 72  h, the biofilm 
was harvested in 0.2  M bicarbonate buffer pH 9.4 and 
dispersed using mild sonication conditions (1  min at 
14 kHz) to obtain a homogeneous resuspension. For the 
coating of ELISA plates, biofilm extracts were normalized 
to  OD600nm of 2 × 10−4.
Histology and immunohistochemistry
The mice’s intestines were sectioned in duodenum, jeju-
num, ileum, cecum, and colon. Each intestinal section 
was knotted in both ends previous to sectioning to avoid 
the loss of the intestinal content. Samples of approxi-
mately 2  cm in length were fixed in 4% formaldehyde. 
After fixation, each sample was dehydrated in alcohol 
solutions of increasing concentration and embedded in 
paraffin. The embedded samples were thin-sectioned at 
2–3 µm and stained with hematoxylin and eosin.
For immunohistochemistry of the mice’s intestinal sec-
tion, the samples were de-paraffinized, rehydrated and 
incubated for 30 min at room temperature with the pri-
mary antibody (rabbit anti-TasA serum). A detection kit, 
containing the secondary antibody and aminoethyl car-
bazole as chromogen, was subsequently applied accord-
ing to the manufacturer’s protocols (Peroxidase/AEC 
Rabbit/Mouse Kit, DAKO). Images were acquired using 
an Olympus CX41 light microscope equipped with a 40X 
objective lens and an Olympus Vanox-S AxioCam inter-
face. The acquired images were processed using Image J 
software (Wayne Rasband, NIH, USA; http://image j.nih.
gov/ij).
Additional files
Additional file 1: Figure S1. Tracking of Bacillus subtilis recombinant in 
the gut of mice. Two mice were orally applied with 5 × 1010 CFU spores/
dose of B. subtilis wild-type (wt) or tasA lux TasA-mCherry strains. (a) 
Feces were monitored for luminescence at 7 days post-application of 
recombinant spores. A color luminescence scale is shown at the right of 
the panel. The luminescent images were acquired with a Xenogen IVIS 
camera and analyzed using Living  Image® 4.0 software (Caliper Life Sci-
ences, USA) (b) Immunohistochemistry of mice cecum sections incubated 
with anti-TasA sera (1:100) followed with secondary anti-rabbit-HRP and 
stained with diaminobenzidine (brown). The cell membranes and nuclei 
were counterstained with eosin (red)/hematoxylin (blue). Scale bar is 100 
µm. (c) Schematic representation of mice oral application of recombinant 
B. subtilis spores schedule. Mice (six females BALB/c, 6 weeks old per 
group) were treated 5 × 1010 CFU spores/ dose on days 1, 21 and 42. The 
experimental groups were the following with (i) placebo (saline solution), 
(ii) wild-type, (iii) tasA lux TasA-mCherry and (iv) tasA sinR lux TasA-mCherry. 
On day 50, animals were sacrificed. (d) Plot of the total number of shed B. 
subtilis spores (CFU) in feces after each oral application. Data represent the 
mean ± SD for each group of animals. (e) Representative histological sec-
tions stained with hematoxylin and eosin from intestinal samples of dogs 
orally inoculated with recombinant B. subtilis spores (placebo, wt, tasA lux 
TasA-mCherry and tasAsinR lux TasA-mCherry). Lm, intestinal lumen. Scale 
bar is 100 µm.
Additional file 2: Figure S2. IgG humoral response. Determination 
of the serological IgG response by indirect ELISA of mice untreated (a) 
or pretreated with ABXs (b) before oral application of recombinant B. 
subtilis spores. The plates were coated with biofilm extract of B. subtilis 
strain (102-207)EgTrp, biofilm extract of B. subtilis tasA/sinR, recombinant 
purified  H6-EgTrp or recombinant purified  H6-mCherry. The tested animal 
groups are indicated. The body weight curve of the indicated mice groups 
untreated (c) or pretreated (d) with antibiotics before oral application with 
recombinant B. subtilis spores. The data represent the mean ± SEM and 
t-test unpaired two-tailed.
Additional file 3: Figure S3. Antibiotic (ABX) cocktail treatment severely 
reduces bacterial microflora. One mouse (untreated, solid dark circle) 
and two mice (ABX 1, solid dark square and ABX 2, open square) were 
untreated or treated with an antibiotic cocktail (ampicillin, gentamycin, 
vancomycin, and metronidazole) in the drinking water, respectively. Feces 
samples of individual cages were collected every day, diluted in PBS and 
cultured by serial dilution in enriched media as (a) Luria-Bertani, (b) Brain-
Heart Infusion and (c) Nutrient Broth. The plots represent the number of 
Log10 CFU/ml from resuspended feces. (d) Plot of the body weight (g) of 
the animals during the 6 days of antibiotic treatment.
Abbreviations
CFU: colony forming unit; TMB: 3,3′,5,5′-tetramethylbenzidine; LB: Luria-Ber-
tani; sIgA: secretory immunoglobulin A; ABX: antibiotic.
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